talkmed group

TW Troy Limited's offer to privatise TalkMed has received clearance from the Competition and Consumer Commission of Singapore; it has also been approved by shareholders.

Companies & Markets

TalkMed to delist from SGX on Sep 15

Scheme consideration payments have been made to shareholders

TalkMed expects the last day for its shares to be traded to be on or around Aug 8.

Companies & Markets

TalkMed shareholders approve Tamarind Health’s privatisation offer

Payment of the scheme consideration is expected to be by Aug 29

65 Equity Partners. From left: Adrienne Teh, managing director; Francis Woo, chief corporate officer and managing director; chief executive Tan Chong Lee; and investment principal Timothy Wee.

Companies & Markets

65 Equity Partners’ two Singapore funds focus on driving growth in companies regardless of former listing status

The fund manager aims to find businesses that are listed offshore which are underappreciated and have an Asian angle, says its CEO

The move by 65 Equity Partners comes against the backdrop of Singapore’s amped-up efforts to revive the ailing local equities market. In 2024, delistings from the Singapore Exchange outpaced new entrants to the bourse.

Columns

HOCK LOCK SIEW

Fund manager 65 Equity Partners’ role in TalkMed privatisation offer is at odds with its core

With one of its funds’ mandate to support companies eyeing an SGX listing, encouraging the medical group’s delisting through the other is a bad look

The offer price is 20 per cent higher than the counter's last traded price of S$0.38 on Apr 5.

Companies & Markets

TalkMed receives S$0.456 per share in privatisation offer via scheme of arrangement

The company says it provides shareholders with an opportunity to ‘realise their investment in the shares at a premium’

TalkMed will update shareholders in due course when it becomes aware of any material developments.

Consumer & Healthcare

Discussions on stake sale still ongoing, says TalkMed

This is its fifth update on the potential deal

TalkMed Group faces growing competition for medical tourists in South-east Asia, due to a strong Singapore dollar.

Consumer & Healthcare

TalkMed H2 net profit dips 2.8% to S$17.9 million despite revenue increase

TERTIARY healthcare services provider TalkMed Group on Tuesday (Feb 20) posted a 2.8 per cent drop in earnings to S$17.9 million for the second half ended Dec 31, 2023, from S$18.4 million in the corr...

TalkMed Group sees its oncology services revenue rise 19.9 per cent to S$37.5 million.

Companies & Markets

TalkMed Group posts 17.7% rise in H1 net profit on improved patient numbers

HEALTHCARE services provider TalkMed Group posted a 17.7 per cent rise in net profit to S$14.3 million for the six months ended Jun 30, 2023, up from S$12.1 million in the corresponding period a year ...

Earnings per share for H2 2022 stood at 1.39 Singapore cents per share, up from 1.08 cents per share in 2021.

Companies & Markets

TalkMed Group posts 29% rise in H2 net profit to S$18.4 million on more patient visits

HEALTHCARE services provider TalkMed Group’s net profit for the second half (H2) rose 28.7 per cent, thanks to higher revenue from more oncology patient visits in Singapore.

TalkMed notes that the lifting of Covid-19 travel restrictions in April 2022 has resulted in an increase in the number of patient visits compared to the same corresponding period last year.

Companies & Markets

TalkMed Group H1 net profit rises 12.2% on higher revenue

HEALTHCARE services provider TalkMed Group reported a 12.2 per cent increase in net profit for its first half ended Jun 30, 2022 on the back of higher revenue.

Latest T-bills Treasury Bills Results & Interest News Latest SSB Singapore Savings Bonds News Latest COE Certificate of Entitlement News

Latest Johor-Singapore SEZ News Latest BTO Build To Order & Sales of Balance News Latest STI Straits Times Index News Latest SGX Dividends, Share Price News Latest Bonds Market News Latest Singapore Stocks To Buy News Latest Singapore Economy News